The DOI matches its Crossref record; 127 of the 127 references it cites were found in a registry or an index; 210 of the 306 sources its claims cite were checked for support.
Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients
Open accessAbstract
Osteosarcoma (OS) is a type of bone cancer that is derived from primitive mesenchymal cells typically affecting children and young adults. The current standard of treatment is a combination of neoadjuvant chemotherapy and surgical resection of the cancerous bone. Post-resection challenges in bone regeneration arise. To determine the appropriate amount of bone to be removed, preoperative imaging techniques such as bone and CT scans are employed. To prevent local recurrence, the current standard of care suggests maintaining bony and soft tissue margins from 3 to 7 cm beyond the tumor. The amount of bone removed in an OS patient leaves too large of a deficit for bone to form on its own and requires reconstruction with metal implants or allografts. Both methods require the bone to heal, either to the implant or across the allograft junction, often in the setting of marrow-killing chemotherapy. Therefore, the issue of bone regeneration within the surgically resected margins remains an important challenge for the patient, family, and treating providers. Mesenchymal stem/stromal cells (MSCs) are potential agents for enhancing bone regeneration post tumor resection. MSCs, used with scaffolds and growth factors, show promise in fostering bone regeneration in OS cases. We spotlight two MSC types—bone marrow-derived (BM-MSCs) and adipose tissue-derived (ASCs)—highlighting their bone regrowth facilitation and immunomodulatory effects on immune cells like macrophages and T cells, enhancing therapeutic outcomes. The objective of this review is two-fold: review work demonstrating any ability of MSCs to target the deranged immune system in the OS microenvironment, and synthesize the available literature on the use of MSCs as a therapeutic option for stimulating bone regrowth in OS patients post bone resection. When it comes to repairing bone defects, both MB-MSCs and ASCs hold great potential for stimulating bone regeneration. Research has showcased their effectiveness in reconstructing bone defects while maintaining a non-tumorigenic role following wide resection of bone tumors, underscoring their capability to enhance bone healing and regeneration following tumor excisions.
Overview
CoChat Summary
TL;DR
This narrative review argues that mesenchymal stem/stromal cells (MSCs), especially bone marrow-derived MSCs (BM-MSCs) and adipose tissue-derived stem cells (ASCs), may promote bone regeneration after osteosarcoma (OS) tumor excision while also modulating macrophages and T cells. However, MSC effects are context-dependent, can be pro-tumorigenic, and require further safety and delivery optimization before therapeutic use.
Key findings
- MSCs can exert both pro- and anti-tumorigenic effects; without modulation, the net effect appears pro-tumorigenic, but priming, drug loading, or MSC-derived extracellular vesicles (EVs) may support anti-tumor therapy. For example, IFN-γ priming transiently upregulates MHC-I and MHC-II, and MSC EVs carrying miRNAs such as miR-16-5p, miR-3940-5p, miR-4461, and miR-15a can reduce metastatic potential or suppress tumor growth, angiogenesis, and invasion.
- BM-MSCs and ASCs show promise for bone regeneration after OS resection. In clinical reports, scaffold-free ASCs in three OS patients produced adequate bone regrowth at 54, 27, and 48 months with no prolonged inflammation or neoplastic growth; two patients receiving 3D osteogenic ASC implants showed osteogenesis without oncological side effects short-term (within 3 months) and long-term (up to 4 years). In another study, all eight patients treated with BM-MSCs in fibrin clots regained limb function at average follow-ups of 6.7 and 76 months, with no excessive tissue growth or tumor development.
- Safety data are mixed. MSC transplantation/infusion in humans is described as safe in some studies: 226 patients receiving human platelet lysate-expanded MSCs showed no malignant transformation over a mean follow-up of 11 months, and chromosomal abnormalities in culture-expanded MSCs were linked to senescence rather than tumorigenesis. However, animal studies showed MSC infusion can promote OS growth and pulmonary metastasis via CCL5, CXCR4/VEGF, and IL-6/STAT3 signaling; anti-IL-6 receptor antibodies halted the pro-tumor effects of tumor extracellular vesicle-educated MSCs.
- MSC immunomodulation is bidirectional: MSCs can polarize M1 macrophages toward an M2 anti-inflammatory phenotype, impair T cell responses, and increase Tregs, but can also promote macrophage/T cell activation and CD8+ cytotoxic T cell function while suppressing Tregs. CD146+ and CD106+ MSC subpopulations are highlighted as having higher immunomodulatory potency.
Methods
- Narrative review with a two-fold objective: review work on MSC ability to target the deranged immune system in the OS microenvironment, and synthesize literature on MSCs for stimulating bone regrowth in OS patients after bone resection.
- Evidence discussed includes in vitro studies, in vivo animal models such as nude mice and OS xenograft models, and clinical studies/case reports involving BM-MSCs or ASCs with scaffolds, growth factors, drug loading, or EVs.
- Main analysis is qualitative synthesis of mechanisms, MSC types, bone regeneration strategies, immunomodulatory effects, and safety considerations; no systematic search strategy, quality appraisal, or meta-analysis is described.
Limitations
- The paper states that further research is needed to fully understand mechanisms of action, optimize MSC delivery methods, and evaluate long-term safety and efficacy. It also lists safety/efficacy challenges in MSC manufacturing, including replacing animal-derived media with regulatory-compliant media, ensuring lack of malignant transformation via genetic stability testing, choosing local versus systemic delivery, and optimizing MSC dose (up to 5 × 10^6 cells/kg of body mass or more).
- The paper notes that MSC function is context-dependent, influenced by tissue origin and the administered tissue microenvironment; the literature is mixed on whether BM-MSCs or ASCs have superior osteogenic potential, and unknown TME effects could subvert MSCs toward pro-tumorigenic activity. It also states that only a limited number of cell-based strategies have been adopted in clinical practice, and none are definitive for delayed/non-union or bone regrowth after tumor excision.
- Evident from the text: as a narrative review, it lacks a systematic search, formal risk-of-bias assessment, or meta-analysis, and many conclusions rely on preclinical models and small clinical series.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
136 Valid · 4 Not valid · 26 Not checked · 20 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“As a result, MSCs have the potential to enhance a pro-tumor microenvironment [25].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.2. Immunomodulatory Properties of MSCs
What the sources say
- Supportedcites [25] Harrell, C.R., Volarevic, A., Djonov, V.G., Jovicic, N., and Volarevic, V. (2021). Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity. Int. J. Mol. Sci., 22. source
Section 2 describes MSCs promoting an immunosuppressive tumor microenvironment that weakens anti-tumor immunity and supports tumor growth. Section 3 also notes their pro-tumorigenic potential while emphasizing that their effects depend on local conditions. Page numbers are not provided in our copy. (LLM, conf=0.92)
states a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A higher level of T cell infiltration is indicative of a better prognosis, whereas a macrophage-predominant infiltration correlates with a worse prognosis [1].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [1] Gonzalez, 2018, Roles of the immune system in cancer: From tumor initiation to metastatic progression, Genes Dev. source
The T cells section states that high T-cell infiltration is associated with favorable prognosis across several cancers. The Macrophages section also reports that high levels of tumor-associated macrophages correlate with poor prognosis, supporting the contrast in the citing sentence. (LLM, conf=0.93)
hedgedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“However, in primary OS, heterogenous TAMs displaying an intermediate phenotype between M1 and M2 have been associated with anti-metastatic effects [4,5].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [4] Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G.E., Santucci, A., Vermi, W., and Giurisato, E. (2020). Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy. Int. J. Mol. Sci., 21. source
The Introduction states that heterogeneous TAMs with an intermediate M1–M2 phenotype have been observed in primary osteosarcoma and associated with anti-metastatic activity. This directly supports the attributed claim. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [5] Buddingh, 2011, Tumor-Infiltrating Macrophages Are Associated with Metastasis Suppression in High-Grade Osteosarcoma: A Rationale for Treatment with Macrophage Activating Agents, Clin. Cancer Res. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, it has been shown that native CD8+ T cells play an immunomodulatory role, more specifically in patients with primary OS [8,9].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Partly supportedcites [8] Tsukahara, 2006, Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5, Cancer Sci. sourceExperimental — accuracy not yet measured
The Results section ('Relationship between HLA class I expression and T-cell infiltration in osteosarcoma tissues') documents that CD8+ T cells were found in all 20 osteosarcoma specimens, so the presence of native CD8+ T cells in primary OS is supported. However, the Discussion only 'suggest[s] that the class I-restricted cytotoxic T lymphocyte pathway plays a major role in immune surveillance of patients with osteosarcoma who undergo multidrug chemotherapy protocols' — a hedged inference drawn from HLA class I expression and survival, not a demonstrated immunomodulatory function of CD8+ T cells; the same Discussion notes the relationship between CD8+ infiltration and HLA class I expression was not statistically significant (P = 0.12, Results). The citing sentence therefore states as established what this source only suggests, and attributes a functional 'immunomodulatory role' that the paper does not itself measure. (LLM, conf=0.70)
- Partly supportedcites [9] Wang, 2016, T-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities, Front. Immunol. sourceExperimental — accuracy not yet measured
The ‘Unmodified CD8+ T Lymphocytes’ section says evidence suggests cytotoxic CD8+ T cells have a leading role in immune surveillance in patients with osteosarcoma. It does not specifically establish that role in patients with primary osteosarcoma, and its wording is more tentative than ‘has been shown.’ (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“As the tumor progresses, the TME induces the TAMs to polarize from an M1 to an M2 phenotype, which is pro-tumorigenic [1].”
§ Mesenchymal Stem/Stromal Cells: Immunomodulatory and Bone Regeneration Potential after Tumor Excision in Osteosarcoma Patients > 1. MSC and the Tumor Microenvironment > 1.1. Harnessing Macrophages and T Cells in the Tumor Microenvironment for Cancer Elimination
What the sources say
- Supportedcites [1] Gonzalez, 2018, Roles of the immune system in cancer: From tumor initiation to metastatic progression, Genes Dev. source
The Macrophages section says anti-tumor macrophages show M1-like polarization during carcinogenesis and that, as tumors progress, the TME elicits a protumorigenic M2-like polarization of TAMs. This supports the citing sentence as a paraphrase. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
96 more claims · 73 with their cited sources checked
Create a free account to see all 186 claims and to verify the 39 references still open.
- Probably not a substantial claim. 32
- It may state two separate claims as one. 60
- Borderline: one of the tests for a substantial claim is unclear. 1
- The quote only partly states this claim. 1
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052
VEGF receptor signalling ? in control of vascular function
Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
TGF-β and BMP Signaling in Osteoblast Differentiation and Bone Formation
Chen, G., Deng, C., & Li, Y.-P. (2012) · International Journal of Biological Sciences · doi:10.7150/ijbs.2929 · Cited by 1,756
Caplan, A. I., & Correa, D. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.06.008 · Cited by 1,682
Macrophage Polarization States in the Tumor Microenvironment
Boutilier, A. J., & Elsawa, S. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136995 · Cited by 1,631
Waterman, R. S., Tomchuck, S. L., Henkle, S. L., & Betancourt, A. M. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010088 · Cited by 1,238
Comparison of Multi-Lineage Cells from Human Adipose Tissue and Bone Marrow
De Ugarte, D. A., Morizono, K., Elbarbary, A., Alfonso, Z., Zuk, P. A., Zhu, M., Dragoo, J. L., Ashjian, P., Thomas, B., Benhaim, P., et al. (2003) · Cells Tissues Organs · doi:10.1159/000071150 · Cited by 1,173
TGF-β1–induced migration of bone mesenchymal stem cells couples bone resorption with formation
Tang, Y., Wu, X., Lei, W., Pang, L., Wan, C., Shi, Z., Zhao, L., Nagy, T. R., Peng, X., Hu, J., et al. (2009) · Nature Medicine · doi:10.1038/nm.1979 · Cited by 1,165
Endothelial cells and VEGF in vascular development
Coultas, L., Chawengsaksophak, K., & Rossant, J. (2005) · Nature · doi:10.1038/nature04479 · Cited by 1,016 · cited 1×
“These proteins collectively contribute to promoting angiogenic activities by influ-encing endothelial cell proliferation [49,53,54].”
BackgroundMaes, C., Kobayashi, T., Selig, M. K., Torrekens, S., Roth, S. I., Mackem, S., Carmeliet, G., & Kronenberg, H. M. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.07.010 · Cited by 940
Mesenchymal Stem/Stromal Cells (MSCs): Role as Guardians of Inflammation
Prockop, D. J., & Youn Oh, J. (2012) · Molecular Therapy · doi:10.1038/mt.2011.211 · Cited by 816
Mesenchymal stem cell–educated macrophages: A novel type of alternatively activated macrophages
Kim, J., & Hematti, P. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2009.09.004 · Cited by 785
Regulation of macrophage development and function in peripheral tissues
Lavin, Y., Mortha, A., Rahman, A., & Merad, M. (2015) · Nature Reviews Immunology · doi:10.1038/nri3920 · Cited by 680 · cited 1×
“With appropriate guidance, they can exert powerful antitumor effects by eliminating cancerous cells, impeding the formation of new blood vessels, and reducing fibrosis [2].”
BackgroundThe role of CD4+ T cell responses in antitumor immunity
Pardoll, D. M., & Topalian, S. L. (1998) · Current Opinion in Immunology · doi:10.1016/s0952-7915(98)80228-8 · Cited by 672
The Critical Need for CD4 Help in Maintaining Effective Cytotoxic T Lymphocyte Responses
Kalams, S. A., & Walker, B. D. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2199 · Cited by 660
Lendeckel, S., Jödicke, A., Christophis, P., Heidinger, K., Wolff, J., Fraser, J. K., Hedrick, M. H., Berthold, L., & Howaldt, H.-P. (2004) · Journal of Cranio-Maxillofacial Surgery · doi:10.1016/j.jcms.2004.06.002 · Cited by 638
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells
Xian, L., Wu, X., Pang, L., Lou, M., Rosen, C. J., Qiu, T., Crane, J., Frassica, F., Zhang, L., Rodriguez, J. P., et al. (2012) · Nature Medicine · doi:10.1038/nm.2793 · Cited by 631
Species Variation in the Mechanisms of Mesenchymal Stem Cell-Mediated Immunosuppression
Ren, G., Su, J., Zhang, L., Zhao, X., Ling, W., L'huillie, A., Zhang, J., Lu, Y., Roberts, A. I., Ji, W., et al. (2009) · Stem Cells · doi:10.1002/stem.118 · Cited by 597
Marcacci, M., Kon, E., Moukhachev, V., Lavroukov, A., Kutepov, S., Quarto, R., Mastrogiacomo, M., & Cancedda, R. (2007) · Tissue Engineering · doi:10.1089/ten.2006.0271 · Cited by 589 · cited 1×
“Specifically, culture-expanded BM-MSCs on ceramic biomaterials result in the complete fusion of bone segmental defects upon transplantation in vivo with enduring results at follow-up 6–7 years post operatively [39,96].”
BackgroundReview on Strategies and Technologies for Exosome Isolation and Purification
Chen, J., Li, P., Zhang, T., Xu, Z., Huang, X., Wang, R., & Du, L. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.811971 · Cited by 585
Kitaori, T., Ito, H., Schwarz, E. M., Tsutsumi, R., Yoshitomi, H., Oishi, S., Nakano, M., Fujii, N., Nagasawa, T., & Nakamura, T. (2009) · Arthritis & Rheumatism · doi:10.1002/art.24330 · Cited by 577
Klopp, A. H., Gupta, A., Spaeth, E., Andreeff, M., & Marini, F. (2011) · Stem Cells · doi:10.1002/stem.559 · Cited by 562 · cited 2×
“Numerous factors must be taken into consideration when determining the effects of MSCs on cancer growth, such as the timing of MSCs being introduced to the TME, as well as the method of MSC delivery, which can affect the type of contact MSCs have with cells of the TME [20].”
BackgroundAdipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison
Mohamed-Ahmed, S., Fristad, I., Lie, S. A., Suliman, S., Mustafa, K., Vindenes, H., & Idris, S. B. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0914-1 · Cited by 515
Buddingh, E. P., Kuijjer, M. L., Duim, R. A. J., Bürger, H., Agelopoulos, K., Myklebost, O., Serra, M., Mertens, F., Hogendoorn, P. C. W., Lankester, A. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2047 · Cited by 508
HEO, J. S., CHOI, Y., KIM, H.-S., & KIM, H. O. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2015.2413 · Cited by 495
Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells
Mesimäki, K., Lindroos, B., Törnwall, J., Mauno, J., Lindqvist, C., Kontio, R., Miettinen, S., & Suuronen, R. (2009) · International Journal of Oral and Maxillofacial Surgery · doi:10.1016/j.ijom.2009.01.001 · Cited by 480 · cited 1×
“Additionally, ASCs, in combination with β -tricalcium phosphate and BMP-2, led to osteo-integrated implants and a full defect reconstruction at 36 months in maxillary reconstruction [39,91].”
BackgroundTormin, A., Li, O., Brune, J. C., Walsh, S., Schütz, B., Ehinger, M., Ditzel, N., Kassem, M., & Scheding, S. (2011) · Blood · doi:10.1182/blood-2010-08-304287 · Cited by 460 · cited 1×
“CD146 expression in MSCs plays a key role in the perivascular niche, skeletogenesis, and hematopoietic support in vivo [26–28].”
BackgroundFates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Qin, Y., Wang, L., Gao, Z., Chen, G., & Zhang, C. (2016) · Scientific Reports · doi:10.1038/srep21961 · Cited by 458 · cited 1×
“Additional research emphasizes the prominence of pro-osteogenic miRNAs, such as miR-196a, miR-27a, and miR-206, within BM-MSCs EVs [49,51,52].”
BackgroundTarte, K., Gaillard, J., Lataillade, J.-J., Fouillard, L., Becker, M., Mossafa, H., Tchirkov, A., Rouard, H., Henry, C., Splingard, M., et al. (2010) · Blood · doi:10.1182/blood-2009-05-219907 · Cited by 430 · cited 2×
“Interestingly, chromosomal abnormalities in culture-expanded MSCs appear to be linked to cell senescence due to extensive passaging, rather than tumorigenesis [41,43,44].”
BackgroundLi, C.-Y., Wu, X.-Y., Tong, J.-B., Yang, X.-X., Zhao, J.-L., Zheng, Q.-F., Zhao, G.-B., & Ma, Z.-J. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0066-5 · Cited by 410 · cited 1×
“Some suggest that BM-MSCs exhibit greater osteogenic capacity [58–62], while others propose that ASCs have equal or superior potential [58,63–66].”
BackgroundTissue Engineering and Cell-Based Therapies for Fractures and Bone Defects
Perez, J. R., Kouroupis, D., Li, D. J., Best, T. M., Kaplan, L., & Correa, D. (2018) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2018.00105 · Cited by 390 · cited 10×
“A major pathway for the recruitment of MSCs to the fracture site is facilitated by signaling pathways like the SDF1/CXC chemokine receptor (CXCR) 4 axis [39,80,81].”
BackgroundInfluentialSelf-citationRecombinant Human Platelet-Derived Growth Factor: Biology and Clinical Applications
Hollinger, J. O., Hart, C. E., Hirsch, S. N., Lynch, S., & Friedlaender, G. E. (2008) · Journal of Bone and Joint Surgery · doi:10.2106/jbjs.g.01231 · Cited by 353 · cited 1×
“Another growth factor significantly influencing angiogenesis and MSCs migration is PDGF, particularly PDGF-BB [39,74].”
BackgroundAdvances in mesenchymal stem cell exosomes: a review
Tang, Y., Zhou, Y., & Li, H.-J. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02138-7 · Cited by 327
PDGF in bone formation and regeneration: New insights into a novel mechanism involving MSCs
Caplan, A. I., & Correa, D. (2011) · Journal of Orthopaedic Research · doi:10.1002/jor.21462 · Cited by 312
LI, X., BAI, J., JI, X., LI, R., XUAN, Y., & WANG, Y. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1821 · Cited by 301
Lin, Z., Wu, Y., Xu, Y., Li, G., Li, Z., & Liu, T. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01650-5 · Cited by 297
Mesenchymal stem cells: Amazing remedies for bone and cartilage defects
Kangari, P., Talaei-Khozani, T., Razeghian-Jahromi, I., & Razmkhah, M. (2020) · Stem Cell Research & Therapy · doi:10.1186/s13287-020-02001-1 · Cited by 286
Xu, L., Liu, Y., Sun, Y., Wang, B., Xiong, Y., Lin, W., Wei, Q., Wang, H., He, W., Wang, B., et al. (2017) · Stem Cell Research & Therapy · doi:10.1186/s13287-017-0716-x · Cited by 284
Tumor-Associated Macrophages in Osteosarcoma: From Mechanisms to Therapy
Cersosimo, F., Lonardi, S., Bernardini, G., Telfer, B., Mandelli, G. E., Santucci, A., Vermi, W., & Giurisato, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155207 · Cited by 280 · cited 2×
“However, in primary OS, heterogenous TAMs displaying an intermediate phenotype between M1 and M2 have been associated with anti-metastatic effects [4,5].”
BackgroundWang, D. S., Miura, M., Demura, H., & Sato, K. (1997) · Endocrinology · doi:10.1210/endo.138.7.5275 · Cited by 254
Xu, J.-F., Yang, G.-H., Pan, X.-H., Zhang, S.-J., Zhao, C., Qiu, B.-S., Gu, H.-F., Hong, J.-F., Cao, L., Chen, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114627 · Cited by 235 · cited 2×
“These miRNAs are regulators of various signaling pathways, including RNA degradation, mRNA surveillance, and the Wnt signaling pathway, contributing to the facilitation of osteogenesis [49,50].”
BackgroundJ. Centeno, C., R. Schultz, J., Cheever, M., Freeman, M., Faulkner, S., Robinson, B., & Hanson, R. (2011) · Current Stem Cell Research & Therapy · doi:10.2174/157488811797904371 · Cited by 234 · cited 1×
“In a study involving 226 patients who received human platelet lysate (hPL)-expanded MSCs for their orthopedic conditions, no malignant transformation was observed during a mean follow-up of 11 months [41,42].”
BackgroundCD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties
Yang, Z. X., Han, Z.-B., Ji, Y. R., Wang, Y. W., Liang, L., Chi, Y., Yang, S. G., Li, L. N., Luo, W. F., Li, J. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059354 · Cited by 225
Xu, W.-T., Bian, Z.-Y., Fan, Q.-M., Li, G., & Tang, T.-T. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.02.022 · Cited by 206
Immunomodulatory properties of mesenchymal stromal cells: an update
Müller, L., Tunger, A., Wobus, M., von Bonin, M., Towers, R., Bornhäuser, M., Dazzi, F., Wehner, R., & Schmitz, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.637725 · Cited by 205 · cited 2×
“More specifically, exposure of MSCs to PGE2 has been shown to result in the polarization of M1 macrophages to the M2 phenotype [24].”
BackgroundTu, B., Du, L., Fan, Q.-M., Tang, Z., & Tang, T.-T. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.06.006 · Cited by 196 · cited 1×
“Recent studies, using the xenograft mouse model of OS, demonstrated that tumor extracellular vesicle-educated MSCs may promote osteosarcoma progression through IL-6 production and lung metastasis through STAT3 activation in tumor cells [119,120].”
BackgroundDmitrieva, R. I., Minullina, I. R., Bilibina, A. A., Tarasova, O. V., Anisimov, S. V., & Zaritskey, A. Y. (2012) · Cell Cycle · doi:10.4161/cc.11.2.18858 · Cited by 195 · cited 1×
“Additionally, BM-MSCs can exhibit signs of senescence early in their growth [55,68].”
BackgroundChemotaxis of human articular chondrocytes and mesenchymal stem cells
Mishima, Y., & Lotz, M. (2008) · Journal of Orthopaedic Research · doi:10.1002/jor.20668 · Cited by 192
Perivascular support of human hematopoietic stem/progenitor cells
Corselli, M., Chin, C. J., Parekh, C., Sahaghian, A., Wang, W., Ge, S., Evseenko, D., Wang, X., Montelatici, E., Lazzari, L., et al. (2013) · Blood · doi:10.1182/blood-2012-08-451864 · Cited by 189
Blocking Tumor-Educated MSC Paracrine Activity Halts Osteosarcoma Progression
Baglio, S. R., Lagerweij, T., Pérez-Lanzón, M., Ho, X. D., Léveillé, N., Melo, S. A., Cleton-Jansen, A.-M., Jordanova, E. S., Roncuzzi, L., Greco, M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2726 · Cited by 187
Wang, Y., Zhang, Z., Chi, Y., Zhang, Q., Xu, F., Yang, Z., Meng, L., Yang, S., Yan, S., Mao, A., et al. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.480 · Cited by 185 · cited 1×
“Interestingly, chromosomal abnormalities in culture-expanded MSCs appear to be linked to cell senescence due to extensive passaging, rather than tumorigenesis [41,43,44].”
BackgroundLiao, J., Shi, K., Jia, Y., Wu, Y., & Qian, Z. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.01.006 · Cited by 181
Galland, S., & Stamenkovic, I. (2020) · The Journal of Pathology · doi:10.1002/path.5357 · Cited by 165 · cited 5×
“It is known that MSCs can exert both stimulatory and inhibitory effects on cancer cell growth, invasion, and metastasis (Table 2) [33].”
BackgroundInfluentialShafiee, A., Seyedjafari, E., Soleimani, M., Ahmadbeigi, N., Dinarvand, P., & Ghaemi, N. (2011) · Biotechnology Letters · doi:10.1007/s10529-011-0541-8 · Cited by 163
Human Adipose Stem Cells: From Bench to Bedside
De Francesco, F., Ricci, G., D'Andrea, F., Nicoletti, G. F., & Ferraro, G. A. (2015) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2014.0608 · Cited by 163
The role of stem cells in fracture healing and nonunion
Fayaz, H. C., Giannoudis, P. V., Vrahas, M. S., Smith, R. M., Moran, C., Pape, H. C., Krettek, C., & Jupiter, J. B. (2011) · International Orthopaedics · doi:10.1007/s00264-011-1338-z · Cited by 160
Espagnolle, N., Guilloton, F., Deschaseaux, F., Gadelorge, M., Sensébé, L., & Bourin, P. (2014) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12168 · Cited by 154
Application of BMP-7 to tibial non-unions: A 3-year multicenter experience
Kanakaris, N. K., Calori, G. M., Verdonk, R., Burssens, P., Biase, P. D., Capanna, R., Vangosa, L. B., Cherubino, P., Baldo, F., Ristiniemi, J., et al. (2008) · Injury · doi:10.1016/s0020-1383(08)70019-6 · Cited by 150 · cited 1×
“BMP-2, BMP-4, BMP-5, BMP-6, and BMP-7 are vital for bone formation and repair, with applications in open tibial fractures and non-unions [39,69,70,79].”
BackgroundTsukahara, T., Kawaguchi, S., Torigoe, T., Asanuma, H., Nakazawa, E., Shimozawa, K., Nabeta, Y., Kimura, S., Kaya, M., Nagoya, S., et al. (2006) · Cancer Science · doi:10.1111/j.1349-7006.2006.00317.x · Cited by 148 · cited 1×
“Additionally, it has been shown that native CD8+ T cells play an immunomodulatory role, more specifically in patients with primary OS [8,9].”
BackgroundSystemic recruitment of osteoblastic cells in fracture healing
Shirley, D., Marsh, D., Jordan, G., McQuaid, S., & Li, G. (2005) · Journal of Orthopaedic Research · doi:10.1016/j.orthres.2005.01.013 · Cited by 141
Rivera‐Cruz, C. M., Shearer, J. J., Neto, M. F., & Figueiredo, M. L. (2017) · Stem Cells International · doi:10.1155/2017/4015039 · Cited by 129
Zheng, Y., Wang, G., Chen, R., Hua, Y., & Cai, Z. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0780-x · Cited by 127
Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system
Wang, X., Chen, H., Zeng, X., Guo, W., Jin, Y., Wang, S., Tian, R., Han, Y., Guo, L., Han, J., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.006 · Cited by 126
Mesenchymal stem cells: mechanisms and role in bone regeneration
Qin, Y., Guan, J., & Zhang, C. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132387 · Cited by 122
Bowles, A. C., Kouroupis, D., Willman, M. A., Perucca Orfei, C., Agarwal, A., & Correa, D. (2020) · Stem Cells · doi:10.1002/stem.3196 · Cited by 120
Self-citationZhao, W., Qin, P., Zhang, D., Cui, X., Gao, J., Yu, Z., Chai, Y., Wang, J., & Li, J. (2019) · Aging · doi:10.18632/aging.102406 · Cited by 115 · cited 1×
“In another study, co-cultures of BM-MSC-derived exosomes with Saos-2, MG-63, and MNNG/HOS OS cells lines led to the increased expression of PVT1, a long, noncoding RNA that contributes to OS growth and metastasis [121].”
BackgroundKim, S.-J., Shin, Y.-W., Yang, K.-H., Kim, S.-B., Yoo, M.-J., Han, S.-K., Im, S.-A., Won, Y.-D., Sung, Y.-B., Jeon, T.-S., et al. (2009) · BMC Musculoskeletal Disorders · doi:10.1186/1471-2474-10-20 · Cited by 111 · cited 1×
“Multiple studies have shown that both ASCs and BM-MSCs can promote bone tissue reconstruction in sites of bone loss with and without multifunctional biomaterials (ceramic, biodegradable polymers, and composite materials) that have been designed to guide bone regeneration [39,90–92].”
BackgroundImam, M. A., Holton, J., Ernstbrunner, L., Pepke, W., Grubhofer, F., Narvani, A., & Snow, M. (2017) · International Orthopaedics · doi:10.1007/s00264-017-3597-9 · Cited by 107 · cited 1×
“Bone marrow aspirate concentrate (BMAC), containing BM-MSCs, also demonstrated efficacy in bone healing of non-unions, outperforming grafts, and minimizing complications in various studies [39,94,95].”
Stem cell‐derived exosomes: A promising strategy for fracture healing
Hao, Z., Lu, J., Wang, S., Wu, H., Zhang, Y., & Xu, S. (2017) · Cell Proliferation · doi:10.1111/cpr.12359 · Cited by 106 · cited 1×
“Additional research emphasizes the prominence of pro-osteogenic miRNAs, such as miR-196a, miR-27a, and miR-206, within BM-MSCs EVs [49,51,52].”
BackgroundTodeschi, M. R., El Backly, R., Capelli, C., Daga, A., Patrone, E., Introna, M., Cancedda, R., & Mastrogiacomo, M. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0490 · Cited by 103 · cited 1×
“Simultaneously, MSCs contribute to new vessel formation, further enhancing fracture healing [39,82].”
BackgroundExosomes: Mediators of bone diseases, protection, and therapeutics potential
Behera, J., & Tyagi, N. (2018) · Oncoscience · doi:10.18632/oncoscience.421 · Cited by 101
Giannotti, S., Trombi, L., Bottai, V., Ghilardi, M., D’Alessandro, D., Danti, S., Dell'Osso, G., Guido, G., & Petrini, M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073893 · Cited by 101
Li, A., Xia, X., Yeh, J., Kua, H., Liu, H., Mishina, Y., Hao, A., & Li, B. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113785 · Cited by 100 · cited 1×
“This process is triggered by the response of MSCs to inflammatory factors released from the bone fracture site, such as PDGFs and BMPs, which activate BMP-Smad1/5/8 signaling, promoting MSC migration [40,77,78].”
BackgroundBabajani, A., Soltani, P., Jamshidi, E., Farjoo, M. H., & Niknejad, H. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00748 · Cited by 99
Tu, B., Zhu, J., Liu, S., Wang, L., Fan, Q., Hao, Y., Fan, C., & Tang, T.-T. (2016) · Oncotarget · doi:10.18632/oncotarget.10219 · Cited by 95 · cited 2×
“Importantly, studies showed that culturing Saos-2 OS cells in MSC-conditioned media (CM) resulted in the protection of OS cells from drug-induced apoptosis [123].”
BackgroundMacrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Luo, Z.-W., Liu, P.-P., Wang, Z.-X., Chen, C.-Y., & Xie, H. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.586580 · Cited by 89
Li, J., Huang, Y., Song, J., Li, X., Zhang, X., Zhou, Z., Chen, D., Ma, P. X., Peng, W., Wang, W., et al. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.08.029 · Cited by 86
Seck, T., Scheppach, B., Scharla, S., Diel, I., Blum, W. F., Bismar, H., Schmid, G., Krempien, B., Ziegler, R., & Pfeilschifter, J. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4967 · Cited by 79
Vériter, S., André, W., Aouassar, N., Poirel, H. A., Lafosse, A., Docquier, P.-L., & Dufrane, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0139566 · Cited by 78 · cited 2×
“In both studies, it was observed over time that all patients experienced favorable general clinical outcomes characterized by successful fracture healing and effective filling of bone defects [89,107,108].”
BackgroundT-Cell-Based Immunotherapy for Osteosarcoma: Challenges and Opportunities
Wang, Z., Li, B., Ren, Y., & Ye, Z. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00353 · Cited by 73
Du, L., Han, X.-G., Tu, B., Wang, M.-Q., Qiao, H., Zhang, S.-H., Fan, Q.-M., & Tang, T.-T. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0745-0 · Cited by 70
Mesenchymal Stem Cell: A Friend or Foe in Anti-Tumor Immunity
Harrell, C. R., Volarevic, A., Djonov, V. G., Jovicic, N., & Volarevic, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212429 · Cited by 67
Dufrane, D., Docquier, P.-L., Delloye, C., Poirel, H. A., André, W., & Aouassar, N. (2015) · Medicine · doi:10.1097/md.0000000000002220 · Cited by 66 · cited 2×
“In both studies, it was observed over time that all patients experienced favorable general clinical outcomes characterized by successful fracture healing and effective filling of bone defects [89,107,108].”
BackgroundMesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy
Sarhadi, V. K., Daddali, R., & Seppänen-Kaijansinkko, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011035 · Cited by 63
Human cells with osteogenic potential in bone tissue research
Dvorakova, J., Wiesnerova, L., Chocholata, P., Kulda, V., Landsmann, L., Cedikova, M., Kripnerova, M., Eberlova, L., & Babuska, V. (2023) · BioMedical Engineering OnLine · doi:10.1186/s12938-023-01096-w · Cited by 58
Bonomi, A., Sordi, V., Dugnani, E., Ceserani, V., Dossena, M., Coccè, V., Cavicchini, L., Ciusani, E., Bondiolotti, G., Piovani, G., et al. (2015) · Cytotherapy · doi:10.1016/j.jcyt.2015.09.005 · Cited by 56 · cited 2×
“The CM of gemcitabine-loaded BM-MSCs led to the cell cycle arrest of ductal pancreatic adenocarcinoma cells [109,110], whereas the CM of paclitaxel-loaded BM-MSCs completely inhibited the proliferation of prostate cancer, glioblastoma, acute lymphoblastic leukemia, malignant pleural mesothelioma,…”
BackgroundRath, S. N., Nooeaid, P., Arkudas, A., Beier, J. P., Strobel, L. A., Brandl, A., Roether, J. A., Horch, R. E., Boccaccini, A. R., & Kneser, U. (2016) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1849 · Cited by 55
Huang, Y., Liu, W., He, B., Wang, L., Zhang, F., Shu, H., & Sun, L. (2020) · Journal of Bone Oncology · doi:10.1016/j.jbo.2020.100280 · Cited by 55
ZHANG, P., DONG, L., YAN, K., LONG, H., YANG, T.-T., DONG, M.-Q., ZHOU, Y., FAN, Q.-Y., & MA, B.-A. (2013) · Oncology Reports · doi:10.3892/or.2013.2619 · Cited by 54
Bosco, D. B., Kenworthy, R., Zorio, D. A. R., & Sang, Q.-X. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0128511 · Cited by 50
Human infrapatellar fat pad mesenchymal stem cells show immunomodulatory exosomal signatures
Kouroupis, D., Kaplan, L. D., & Best, T. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-07569-7 · Cited by 50
Self-citationFu, K., Xu, Q., Czernuszka, J., Triffitt, J. T., & Xia, Z. (2013) · Biomedical Materials · doi:10.1088/1748-6041/8/6/065007 · Cited by 49
Advances of Stem Cell-Laden Hydrogels With Biomimetic Microenvironment for Osteochondral Repair
Xu, B., Ye, J., Yuan, F.-Z., Zhang, J.-Y., Chen, Y.-R., Fan, B.-S., Jiang, D., Jiang, W.-B., Wang, X., & Yu, J.-K. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00247 · Cited by 48
Human adipose tissue derived mesenchymal stem cells are resistant to several chemotherapeutic agents
Liang, W., Xia, H., Li, J., & Zhao, R. C. (2011) · Cytotechnology · doi:10.1007/s10616-011-9374-5 · Cited by 47
FGF-2 Angiogenesis in Bone Regeneration Within Critical-Sized Bone Defects in Rat Calvaria
Kigami, R., Sato, S., Tsuchiya, N., Yoshimakai, T., Arai, Y., & Ito, K. (2013) · Implant Dentistry · doi:10.1097/id.0b013e31829d19f0 · Cited by 46
Wu, W., Le, A. V., Mendez, J. J., Chang, J., Niklason, L. E., & Steinbacher, D. M. (2015) · Tissue Engineering Part A · doi:10.1089/ten.tea.2014.0115 · Cited by 44
Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Kouroupis, D., Kaplan, L. D., Huard, J., & Best, T. M. (2023) · Cells · doi:10.3390/cells12141824 · Cited by 41
Self-citationNicolay, N. H., Perez, R. L., Rühle, A., Trinh, T., Sisombath, S., Weber, K.-J., Ho, A. D., Debus, J., Saffrich, R., & Huber, P. E. (2016) · Scientific Reports · doi:10.1038/srep20035 · Cited by 41 · cited 2×
“Also, typical MSC-related surface markers, CD73, CD90, and CD105, show stable expression levels upon cisplatin exposure [109,115].”
BackgroundLeñero, C., Kaplan, L. D., Best, T. M., & Kouroupis, D. (2022) · Cells · doi:10.3390/cells11244002 · Cited by 39
Self-citationDrug-releasing mesenchymal cells strongly suppress B16 lung metastasis in a syngeneic murine model
Pessina, A., Leonetti, C., Artuso, S., Benetti, A., Dessy, E., Pascucci, L., Passeri, D., Orlandi, A., Berenzi, A., Bonomi, A., et al. (2015) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0200-3 · Cited by 39 · cited 3×
“Ewing’s sarcoma was the most sensitive to the CM of paclitaxel-loaded ASCs compared to the other cancer cells [109,114].”
BackgroundGuiho, R., Biteau, K., Grisendi, G., Taurelle, J., Chatelais, M., Gantier, M., Heymann, D., Dominici, M., & Redini, F. (2016) · International Journal of Cancer · doi:10.1002/ijc.30402 · Cited by 38
Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice
Stamatopoulos, A., Stamatopoulos, T., Gamie, Z., Kenanidis, E., Ribeiro, R. D. C., Rankin, K. S., Gerrand, C., Dalgarno, K., & Tsiridis, E. (2019) · Journal of Bone Oncology · doi:10.1016/j.jbo.2019.100231 · Cited by 37 · cited 4×
“Additionally, other potential anti-tumor effects of MSCs are related to apoptosis via the upregulation of TNF-related apoptosis-inducing ligand (TRAIL), G1 arrest, and expression of tumor suppressor genes [36].”
BackgroundMethodInfluentialKouroupis, D., Kaplan, L. D., Huard, J., & Best, T. M. (2023) · doi:10.20944/preprints202305.1465.v1 · Cited by 36
Self-citationSeck, T. L. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.83.7.2331 · Cited by 36
Clavreul, A., Pourbaghi-Masouleh, M., Roger, E., Lautram, N., Montero-Menei, C. N., & Menei, P. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0605-2 · Cited by 35
Smakaj, A., De Mauro, D., Rovere, G., Pietramala, S., Maccauro, G., Parolini, O., Lattanzi, W., & Liuzza, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063057 · Cited by 31
Aanstoos, M. E., Regan, D. P., Rose, R. J., Chubb, L. S., & Ehrhart, N. P. (2016) · Clinical Orthopaedics & Related Research · doi:10.1007/s11999-015-4362-2 · Cited by 28 · cited 2×
“Subsequently, the researchers conducted the resection of the tumor upon maturation of the OS model [102,103].”
BackgroundMethodBMP‐6 and BMPR‐1a are up‐regulated in the growth plate of the fractured tibia
Fischerauer, E. E., Manninger, M., Seles, M., Janezic, G., Pichler, K., Ebner, B., & Weinberg, A. M. (2013) · Journal of Orthopaedic Research · doi:10.1002/jor.22238 · Cited by 27
He, L., Zhou, Q., Zhang, H., Zhao, N., & Liao, L. (2023) · Nanomaterials · doi:10.3390/nano13061083 · Cited by 26
TGF-β1 and BMP-4 carried by liposomes enhance the healing process in alveolar bone
Ferreira, C. L., Abreu, F. A. M. D., Silva, G. A. B., Silveira, F. F., Barreto, L. B. A., Paulino, T. D. P., Miziara, M. N., & Alves, J. B. (2013) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2012.11.013 · Cited by 24
Epigenetic control of mesenchymal stem cells orchestrates bone regeneration
Wang, X., Yu, F., & Ye, L. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1126787 · Cited by 24 · cited 1×
“The literature surrounding the use of genetically modified MSCs as well as MSCs on synthetic scaffolds has shown positive results in terms of promoting osteogenic differentiation of MSCs and bone regrowth in both animal and human studies [87,88].”
BackgroundHerrmann, M., Stanić, B., Hildebrand, M., Alini, M., & Verrier, S. (2019) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.2902 · Cited by 23
Impact of Immunotherapy on CD4 T Cell Phenotypes and Function in Cancer
Saillard, M., Cenerenti, M., Romero, P., & Jandus, C. (2021) · Vaccines · doi:10.3390/vaccines9050454 · Cited by 23
Rabie, A. B. M., & Lu, M. (2004) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2004.05.012 · Cited by 22 · cited 1×
“Additionally, it has been shown that FGF can upregulate VEGF, which contributes to an environment that promotes osteogenesis and angiogenesis [39,85].”
BackgroundJo, Y., Sarkar, N., & Bose, S. (2023) · Journal of Materials Chemistry B · doi:10.1039/d2tb02210a · Cited by 22
Bahrambeigi, V., Ahmadi, N., Moisyadi, S., Urschitz, J., Salehi, R., & Haghjooy Javanmard, S. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-255 · Cited by 21
Pulmonary metastasis of osteosarcoma: multiple presentations in a single patient
Albuquerque M. Silva1, J., Marchiori2, E., Carvalho de Macedo1, F., Ricardo Garcia da Silva1, P., & Brandão Amorim1, 3. (2022) · Jornal Brasileiro de Pneumologia · doi:10.36416/1806-3756/e20210478 · Cited by 19
Tharakan, S., Raja, I., Pietraru, A., Sarecha, E., Gresita, A., Petcu, E., Ilyas, A., & Hadjiargyrou, M. (2023) · Gels · doi:10.3390/gels9040274 · Cited by 18 · cited 2×
“In addition to other biomaterials, hydrogels, with their biocompatibility, bioactivity, biodegradability, and osteoinductive attributes, hold promise in targeting residual tumor areas within bone defects and promoting the natural regeneration of bone at the injury site [97].”
BackgroundGiannotti, S., Trombi, L., Bottai, V., Ghilardi, M., D'Alessandro, D., Danti, S., Dell'Osso, G., Guido, G., & Petrini, M. (2013) · PLoS ONE · doi:10.1371/annotation/e4403abb-b80e-43c5-be74-1bdb2c899d1c · Cited by 12
Isolation of Extracellular Vesicles Derived from Mesenchymal Stromal Cells by Ultracentrifugation
Ramirez-Bajo, M., Banon-Maneus, E., Rovira, J., Campistol, J. M., & Diekmann, F. (2020) · BIO-PROTOCOL · doi:10.21769/bioprotoc.3860 · Cited by 10
LEE, S.-W., JEON, T. J., & BISWAL, S. (2015) · Oncology Reports · doi:10.3892/or.2015.3711 · Cited by 10 · cited 1×
“They found that low concentrations of injected ASCs into a tumor xenograft led to the inhibition of OS tumor growth, while higher concentrations of injected ASCs led to the stimulation of tumor growth [102–105].”
BackgroundThe Safety of Non-Expanded Multipotential Stromal Cell Therapies
Kouroupis, D., Wang, X. N., El-Sherbiny, Y. M., McGonagle, D., & Jones, E. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-59165-0_4 · Cited by 9
Self-citationSafety, Ethics and Regulations
(2017) · Stem Cells in Clinical Applications · doi:10.1007/978-3-319-59165-0 · Cited by 4
Cited by
Kostadinova, M., Raykovska, M., Simeonov, R., Lolov, S. R., & Mourdjeva, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040287 · Cited by 42
Li, J., Bai, Y., Zhang, H., Chen, T., & Shang, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1445555 · Cited by 27
Dehkordi, M. J., Bahrami, A., Abbasi, M. S., Mokhtari, M. A., Laybidi, F. H., Roosefid, A., Abari, A. H., & Mehr, M. Y. (2024) · Coatings · doi:10.3390/coatings14121522 · Cited by 12
Adaptive smart hydrogels driving precision bone healing in pathological contexts
Huang, H., Xiao, T., Li, Y., Ning, C., Tan, G., & Zhou, L. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.114617 · Cited by 13
Hao, J., Yu, X., Tang, K., Ma, X., Lu, H., & Wu, C. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.06.016 · Cited by 10
Metadata
- Authors
- Baron, M., Drohat, P., Crawford, B., Hornicek, F. J., Best, T. M., & Kouroupis, D.
- Affiliations
- University of Miami (US)
- Corresponding author
- Kouroupis, Dimitrios
- ORCID
- Venue
- Bioengineering
- Publisher
- MDPI AG
- Published
- 2023-10-13
- Volume
- 10
- Issue
- 10
- Pages
- 1187
- ISSN
- 2306-5354 (ISSN-L)
- PMC
- PMC10604230
- OpenAlex
- W4387615496
- Cited by
- 19
- References
- 127
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 7
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Bioengineering (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5R21AR080388-02)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Physical Sciences › Engineering › Biomedical Engineering › Bone Tissue Engineering Materials
- Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
- Keywords
- osteosarcoma, mesenchymal stem cells, bone regeneration, immunomodulation, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, tumor resection, bone defect repair, tumor microenvironment, macrophages, T cells, neoadjuvant chemotherapy, bone marrow
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
